Luke Rudmik1. 1. Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Richmond Road Diagnostic and Treatment Centre, University of Calgary, 1820 Richmond Road SW, Calgary, AB, T2T 5C7, Canada. Lukerudmik@gmail.com.
Abstract
PURPOSE OF REVIEW: The objective of this article is to provide an updated review of the economic burden of chronic rhinosinusitis (CRS) and discuss how both medical and surgical interventions impact direct and indirect costs related to CRS. By understanding the economics of CRS, clinicians may improve the patient-centeredness of their care and help distinguish between low and high value interventions. RECENT FINDINGS: Direct costs related to CRS are primarily driven by outpatient physician visits, prescription medical therapy, and endoscopic sinus surgery (ESS). CRS produces large indirect costs and these costs often vary based on the severity of the patients CRS-specific QoL impairment. The overall direct cost related to CRS is estimated to range between $10 and $13 billion per year in the USA. The overall indirect cost related to CRS-related losses in work productivity is estimated to be in excess of $20 billion per year. In the appropriate patients with refractory CRS, ESS provides significant reductions in both direct and indirect costs; however, continued medical therapy alone may be a high value intervention in select patients who have lower severity in their baseline QoL and work productivity.
PURPOSE OF REVIEW: The objective of this article is to provide an updated review of the economic burden of chronic rhinosinusitis (CRS) and discuss how both medical and surgical interventions impact direct and indirect costs related to CRS. By understanding the economics of CRS, clinicians may improve the patient-centeredness of their care and help distinguish between low and high value interventions. RECENT FINDINGS: Direct costs related to CRS are primarily driven by outpatient physician visits, prescription medical therapy, and endoscopic sinus surgery (ESS). CRS produces large indirect costs and these costs often vary based on the severity of the patientsCRS-specific QoL impairment. The overall direct cost related to CRS is estimated to range between $10 and $13 billion per year in the USA. The overall indirect cost related to CRS-related losses in work productivity is estimated to be in excess of $20 billion per year. In the appropriate patients with refractory CRS, ESS provides significant reductions in both direct and indirect costs; however, continued medical therapy alone may be a high value intervention in select patients who have lower severity in their baseline QoL and work productivity.
Entities:
Keywords:
Burden of disease; Chronic sinusitis; Cost; Economic; Pharmacoeconomics; Rhinosinusitis; Value of care
Authors: Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald Journal: Rhinology Date: 2012-03 Impact factor: 3.681
Authors: Luke Rudmik; Zachary M Soler; Claire Hopkins; Rodney J Schlosser; Anju Peters; Andrew A White; Richard R Orlandi; Wytske J Fokkens; Richard Douglas; Timothy L Smith Journal: Rhinology Date: 2016-06 Impact factor: 3.681
Authors: Layal Chaker; Abby Falla; Sven J van der Lee; Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Raha Pazoki; Oscar H Franco Journal: Eur J Epidemiol Date: 2015-04-03 Impact factor: 8.082
Authors: Whitney W Stevens; Anju T Peters; Bruce K Tan; Aiko I Klingler; Julie A Poposki; Kathryn E Hulse; Leslie C Grammer; Kevin C Welch; Stephanie S Smith; David B Conley; Robert C Kern; Robert P Schleimer; Atsushi Kato Journal: J Allergy Clin Immunol Pract Date: 2019-05-22
Authors: Jordan R Kuiper; Annemarie G Hirsch; Karen Bandeen-Roche; Agnes S Sundaresan; Bruce K Tan; Robert C Kern; Robert P Schleimer; Brian S Schwartz Journal: J Occup Environ Med Date: 2019-08 Impact factor: 2.162
Authors: Kristen L Yancey; Anne S Lowery; Rakesh K Chandra; Naweed I Chowdhury; Justin H Turner Journal: Int Forum Allergy Rhinol Date: 2019-08-27 Impact factor: 3.858
Authors: Andrew J Thomas; Kristine A Smith; Christopher I Newberry; Brandon Cardon; Brock Davis; Zhining Ou; Angela P Presson; Jeremy D Meier; Jeremiah A Alt Journal: Int Forum Allergy Rhinol Date: 2018-08-17 Impact factor: 3.858
Authors: Jose L Mattos; Campbell Edwards; Rodney J Schlosser; Madison Hyer; Jess C Mace; Timothy L Smith; Zachary M Soler Journal: Int Forum Allergy Rhinol Date: 2019-08-20 Impact factor: 3.858